Venus Remedies, a company in the Pharmaceuticals industry, reported revenue of ₹219 crore and net profit of ₹26 crore for the September 2026 quarter.
Venus Remedies (NSE: VENUSREM-BE) closed at ₹1,236.00 on 30 Oct 2026. Its market capitalisation is ₹1,652 crore and it trades at 13.6 times earnings.
Incorporated in 1989, Venus Remedies Ltd is a research-based pharmaceutical company focused on complex injectable formulations across critical care, oncology, anti-infectives and specialty therapies. It operates across 100+ countries, with a product basket of 195+, 1,100+ marketing authorisations and 700+ dossiers filed.{# {# https://www.bseindia.com/xml-data/corpfiling/AttachHis/29971821-bfab-4659-a9d8-7cf5dc170d02.pdf#page=36 #} #}
Descriptive research only, not investment advice. Evenstocks is not a SEBI-registered investment adviser.